SCHEMBL19639657

SCHEMBL19639657

CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2)CCC(=O)N3)ncc1C(F)(F)F

nearest known ligand 0.72

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 12/20 0.72
PTK2B Q14289 8/20 0.61
PTK2 Q05397 6/20 0.61
CDK1 P06493 1/20 0.61
CCNB1 P14635 1/20 0.61
CDK7 P50613 1/20 0.61
INSR P06213 1/20 0.53
ALK Q9UM73 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19654221 0.88 ULK1 (0.55) ULK1PTK2BPTK2CDK1CCNB1
SCHEMBL1474763 0.88 ULK1 (0.63) ULK1PTK2BPTK2CDK1CCNB1
SCHEMBL1476601 0.86 ULK1 (0.68) ULK1PTK2BPTK2CDK1CCNB1
SCHEMBL1231809 0.86 ULK1 (0.53) ULK1PTK2BPTK2CDK1CCNB1
SCHEMBL886537 0.85 INSR (0.71) ULK1PTK2BPTK2CDK7INSR
SCHEMBL17547498 0.85 ULK1 (0.75) ULK1PTK2BPTK2CDK1CCNB1
SCHEMBL29575705 0.84 PTK2B (0.82) ULK1PTK2BPTK2CDK1CCNB1
SCHEMBL17545058 0.84 PTK2B (0.82) ULK1PTK2BPTK2CDK1CCNB1
SCHEMBL17544782 0.84 ULK1 (1.00) ULK1PTK2BPTK2CDK1CCNB1
SCHEMBL17544613 0.84 ULK1 (0.78) ULK1PTK2BPTK2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4070795-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME Salk Institute for Biological Studies (US) 2022-10-12 EP disclosed
EP-3185868-B1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INST FOR BIOLOGICAL STUDI (US) 2022-04-06 EP disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 US disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 US disclosed
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-08-15 US disclosed
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-08-15 US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689397-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885PTK2B 781/4885PTK2 742/4885
US-10266549-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885PTK2B 781/4885PTK2 742/4885
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885PTK2B 813/4885PTK2 884/4885
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885PTK2B 813/4885PTK2 884/4885
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885PTK2B 813/4885PTK2 884/4885
US-10774092-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885PTK2B 781/4885PTK2 742/4885
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885PTK2B 813/4885PTK2 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.